So are about 70% of all stocks. Keep on tossing stuff out, you're bound to be right about something at some point. NOW it's EOD. Always so tough to know when to take somebody seriously on these message boards. You're clearly not one of those people.
There's one piece of news out today, the stock is down pretty big, you can't say there's no connection between the two events, and you're throwing out a bunch of stuff with absolutely no basis. And I'm obviously wasting my time.
Please don't be so definitive when you obviously don't know, a fact that's made obvious by your ridiculous comment about CRL or black box.
I think you should say thank you for that entry point. After all, how much value was anyone giving the antibiotic program. Typical overreaction to something most don't understand.
if the ceo isn't doing his job then that means the r&d pipeline doesn't have good prospects. so, if the pipeline stinks and the ceo smells even worse, why do you hang around?
The ceo's job is to build shareholder value and the ceo of a developmental stage biotech company does that by developing a drug pipeline. Stockathlete is right, you have to be patient. If you don't think he's doing a good job, vote by selling your shares. On the other hand, if you like the company's new-drug prospects, again, you have to be patient. The ceo can only do so much in moving the stock price up....
3DimensionalResearch research recently recommended PKG, you can see their very comprehensive report on SeekingAlpha. They also recommended IP several years ago, but they closed out that position some time ago, according to the 3DR website.
Sentiment: Strong Buy
Whether it's 2.5 million or 5.5 million or 15.5 million, the exercise of those options have no bearing on the market price since it's the company issuing the shares. If anything, it's not a good thing because the number of shares outstanding is increasing.
It's a non-story as far as I'm concerning. We all want good news but let's not create fiction that some folks will look forward to, in vain.
I have no basis to comment on SNY buying MNKD shares but your point about officers and directors exercising their options and buying stock has one major flaw. When company issued options are exercised, the insiders are buying stock directly from the company, meaning no upward pressure on the stock price or any pressure on shorts.
As you've noted, the company had 4 major milestones achieved since August 2013. So, you concede management has done what they set out to do. As for dilution, would you have preferred if they folded up and closed shop due to lack of funds? They obviously did what they had to do to keep things going. The stock price, meantime, is completely out of their control. Management does what it has to do and hopes investors will reward it with a good stock price. For this we wait. As for only Alfred Mann benefiting from the dilution, what the heck are you talking about? How did he benefit from the dilution? His ownership stake didn't increase all that much even though he put in a lot more money to keep things going. Please grow up or sell your shares and get lost.
I don't think your revenue projections are outrageous and the other numbers are probably achievable, depending on how costs are allocated. Just out of curiosity, could you tell us your professional background, you clearly have some experience in the business.
I was also surprised to see the HSR requirement for the deal between MNKD and SNY. What antitrust concerns could there be in a licensing deal for a newly approved drug?
I've appreciated some of your comments but have been frustrated by far more. You're like a petulant little baby always whining about one thing or another. When you whine, you also become a little ridiculous. Just in the comment that I'm responding to, how the heck does the company do something that doesn't serve the interest of all shareholders but benefit Al Mann when he's the largest shareholder by far.???? Anyway, I know there's no point trying to keep your silly typing fingers off the keyboard.
viagra was developed internally. lipitor came with the warner-lambert acquisition, which cost 50 or 60 billion dollars, don't recall the exact amount. it was a huge deal.
You seem to follow the obesity sector very closely. I couldn't find any recent developments on "Treat and Reduce Obesity Act of 2013." How would you gauge the prospects of any of the three - contrave, belveq, and qsymia - gaining medicare coverage anytime soon? I'm also wondering if you have any pricing data on the three drugs. Thanks. I agree with your assessment of OREX.
I'm not saying shorts don't generally do their homework but they're often also wrong, just like longs are often wrong. Shorts have been wrong on MNKD for eight points (or 400%), in fact they've gotten nothing right in the past three years. And Ackman, who has spent more than 18 months and $50 million doing his homework has been miserably wrong thus far on Herbalife. So, I wouldn't sell the shorts short but let's not give them too much credit.
Sentiment: Strong Buy